Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in France / NCT05843604
Recruiting Observational

Cerebral and Cognitive Markers of Treatment Resistance in Obsessive Compulsive Disorder

NCT05843604 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Henri Laborit
Phase
Observational
Started
2023-07-03
Last updated
2026-01-13

Condition(s) studied

OCD

Investigational drug(s) / intervention(s)

Functional MRI

Functional MRI: Three cognitive tests will be performed in the MRI, namely a stroop task, an N-back task and a switching task

Study summary

This study aims to define individual profiles of treatment resistants in order to find indicators and predictors of the therapeutic response.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Obsessive compulsive disorder diagnosed according to Diagnostic and Statistical Manual 5 criteria (patients will be included regardless of the severity and resistance of their pathology and their levels of executive functions) * Understand and accept the constraints of the study * Be a beneficiary or affiliated to a Health Insurance scheme Exclusion Criteria: * Present one of the diagnoses according to the criteria of the DSM 5: schizophrenic disorders, substance abuse or dependence to a substance according to the criteria of the M.I.N.I. version 5.0 (Sheehan et al., 1998) * Generalized anxiety disorder, social anxiety, nicotine dependence and history of a major depressive episode are not exclusion criteria according to the M.I.N.I. version 5.0 (Sheehan et al., 1998) * Have a serious intercurrent pathology * Being a pregnant woman * Being a woman of childbearing age without effective contraception. * Being hospitalized under duress or on an outpatient basis in a care program * Being under judicial protection (reinforced curatorship, guardianship)

Primary outcome measure(s)

  • Cerebral activity modification during N-back task — Day 1
    Blood-oxygen-level-dependent (BOLD) modification during the task between obsessive compulsive disorder patients and controls
  • Cerebral activity modification during Stroop task — Day 1
    Blood-oxygen-level-dependent (BOLD) modification during the task between obsessive compulsive disorder patients and controls
  • Cerebral activity modification during switching task (Monsell et Mizon task ) — Day 1
    Blood-oxygen-level-dependent (BOLD) modification during the task between obsessive compulsive disorder patients and controls

Trial sites (1)

FacilityCityRegionStatus
Centre Hospitalier Henri Laborit Poitiers France Recruiting

More Centre Hospitalier Henri Laborit trials in France

Self-Dehumanization and Hesitation to Report Domestic Violence Recruiting
Nursing Care of Bipolar Patients With Sleeping Disorders Using Luminotherapy and /or Psychoeducation Program (BIPLUMINO) Recruiting
Comparative Study of Gender Identity Disorder Versus Control Recruiting
Evaluation of Membrane Phospholipid and Energy Metabolism in Subjects at High Risk of Psychotic Transition Recruiting
Reducing Mental Health Stigmatization Among Healthcare Workers and Students Using a Virtual Reality Protocol: The VIRTUS Protocol Recruiting

Other trials for the same condition

Objective Characterizatoion of Repetitive Behaviors Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05843604 on ClinicalTrials.gov ↗ ← All trials in France